Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis

[1] Yancy CW(2013)2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 128 1810-1852

[2] Jessup M(2014)2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 507-520

[3] Bozkurt B(2008)Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis Nephrol Dial Transplant 23 3704-3710

[4] Butler J(2003)Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction J Am Coll Cardiol 42 201-208

[5] Casey DE(2008)Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial Am J Kidney Dis 52 501-506

[6] Drazner MH(2006)Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis–a randomized study Nephrol Dial Transplant 21 2507-2512

[7] Fonarow GC(2016)Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis Nephrol Dial Transplant 43 S1-S290

[8] Geraci SA(2004)K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 48 S98-S129

[9] Horwich T(2006)Clinical practice guidelines for peritoneal dialysis adequacy Am J Kidney Dis 80 978-985

[10] Januzzi JL(2011)Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients Kidney Int 148 99-104

[1] Yancy CW(2013)2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 128 1810-1852

[2] Jessup M(2014)2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 507-520

[3] Bozkurt B(2008)Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis Nephrol Dial Transplant 23 3704-3710

[4] Butler J(2003)Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction J Am Coll Cardiol 42 201-208

[5] Casey DE(2008)Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial Am J Kidney Dis 52 501-506

[6] Drazner MH(2006)Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis–a randomized study Nephrol Dial Transplant 21 2507-2512

[7] Fonarow GC(2016)Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis Nephrol Dial Transplant 43 S1-S290

[8] Geraci SA(2004)K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 48 S98-S129

[9] Horwich T(2006)Clinical practice guidelines for peritoneal dialysis adequacy Am J Kidney Dis 80 978-985

[10] Januzzi JL(2011)Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients Kidney Int 148 99-104